76006-11-6

Usage

Uses

Used in Pharmaceutical Research and Development:
7-Chloro-1H-pyrazolo[3,4-c]pyridine is used as a key intermediate in the synthesis of various pharmaceutical compounds for [application reason]. Its unique structure and chemical properties make it a valuable building block in the creation of new drugs and therapeutic agents.
Used in Chemical Product Development:
7-Chloro-1H-pyrazolo[3,4-c]pyridine is used as a chemical intermediate in the production of a range of chemical products for [application reason]. Its distinctive structure and strong bonding affinity contribute to the development of innovative materials and compounds in various industries.

InChI:InChI=1/C6H4ClN3/c7-6-5-4(1-2-8-6)3-9-10-5/h1-3H,(H,9,10)

Upstream product

• 76006-12-7 1H-pyrazolo<3,4-c>pyridine-7(6H)-thione 
• 76006-00-3 3-acetamido-2-chloro-4-methylpyridine 
• 21901-18-8 2-hydroxy-4-methyl-3-nitropyridine 
• 6635-86-5 2-amino-4-methyl-3-nitropyridine 
• 133627-45-9 3-Amino-2-chloro-4-methylpyridine 
• 23056-39-5 2-chloro-3-nitro-4-methylpyridine 
• 76005-98-6 3-acetamido-2-methoxy-4-methylpyridine 
• 76006-10-5 7-methoxy-1H-pyrazolo<3,4-c>pyridine 
• 76006-09-2 1H-pyrazolo<3,4-c>pyridin-7(6H)-one 
• 76005-99-7 2-methoxy-3-amino-4-methylpyridine 

Relevant academic research and scientific papers

Synthesis, docking study and kinase inhibitory activity of a number of new substituted pyrazolo[3,4-c]pyridines

A series of new pyrazolo[3,4-c]pyridines bearing various 1, 3, 5 or 1, 3, 7 pattern substitutions, were designed and synthesized. Some of them showed interesting inhibitory activity mainly against glycogen synthase kinase 3 (GSK3)α/β as well as against cdc2-like kinases 1 (CLK1) and dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A), with good selectivity and remarkable structure-activity relationships (SARs), without being cytotoxic. Molecular simulations in correlation with biological data revealed the importance of the existence of N1-H as well as the absence of a bulky 7-substituent.

Synthesis and Antiproliferative Activity of New pyrazolo[3,4-c]pyridines

Background: Several pyrazolopyridines possess promising pharmacological activities, mainly attributed to their antagonistic nature towards the natural purines in many biological processes. Cytotoxicity and anticancer potential of this class of compounds a

PERFLUORINATED 5,6-DIHYDRO-4H-1,3-OXAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE

The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: wherein variables A4, A5, A6, A8, each of R1 and R2, R3 and R7 of Formula I, independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and corresponding uses of the compounds and compositions for treatment of disorders and/or conditions related to A-beta plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions. The invention further provides compounds of Formulas II and III, and sub-formula embodiments thereof, intermediates and processes and methods useful for the preparation of compounds of Formulas I-III.

PYRROLIDINE DERIVATIVES AND THEIR USE AS COMPLEMENT PATHWAY MODULATORS

The present invention provides a compound of formula (I) a method for manufacturing the compounds of the invention, and its therapeutic uses as a factor D inhibitor for the treatment of ophthalmic diseases. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

COMPLEMENT PATHWAY MODULATORS AND USES THEREOF

The present invention provides a compound of formula I: a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

PYRROLIDINE DERIVATIVES AND THEIR USE AS COMPLEMENT PATHWAY MODULATORS

The present invention provides a compound of formula (I) a method for manufacturing the compounds of the invention, and its therapeutic uses as complement pathway modulators for the treatment of ocular diseases. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

INDOLE COMPOUNDS OR ANALOGUES THEREOF USEFUL FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD)

The present invention provides a compound of formula (I): a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

Synthesis of 7-aminopyrazolo[3,4-c]pyridine as a probe for the preparation of compounds of pharmacological interest

A synthetic route towards the preparation of 7-aminopyrazolo[3,4-c]pyridine is developed, starting from the readily accessible 2-amino-4-methyl-3-nitropyridine. The unexpected formation of 7-methylimidazolo[4,5-b]pyridin-2-one during the reaction sequence is also described.

Pyrazolopyridines. Part 5. Preparation and Reactions of Pyrazolopyridines

A series of pyrazolopyridines has been prepared by nitrosation of 3-acetamido-4-methylpyridines and subsequent rearrangement and cyclisation of the N-acetyl-N-nitroso-compounds produced.The reactions of the pyrazolopyridines have been investigated. 1- and 2-Acetyl and 1- and 2-benzyl compounds were obtained and their structures elucidated spectroscopically.The ring system readily undergoes electrophilic substitution in the 3-position. 7-Chloropyrazolopyridine has been shown to be more susceptible to nucleophilic substitution than the isomeric 5-chloro-compound.